hotspot -WSS

hotspot

author：comprehensive 2025-09-28 20:44:30 - browse：99717

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Physicians and social media: If you see something, say something?

hotspot

WSS

U.K. researchers warn about biases in medical devices, algorithms

Plastic surgeons increase patient psychiatric screenings

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Why you shouldn’t ask, “What country has the best health care?”

Syphilis numbers in the United States reach record heights

Why Medicare shouldn’t cover every FDA

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Venture capital firm's plans to take over Akron hospital face hurdles

Novavax promises a turnaround & Lilly roils the obesity market

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

SCOTUS questions limit to govt efforts to fight misinformation

Moonlake's readout produced a cash windfall. Risks remain

Biogen walks away from Aduhelm, years after polarizing approval

Supreme Court strikes down use of affirmative action

Future doctors should be trained to promote social change

leisure time

White House pharmacy plagued with problems, investigation finds

10 reasons why health care startups fail

Positive childhood experiences can help future health

The Affordable Care Act has saved billions in health care costs

Philips to halt sales of sleep apnea machines in U.S.

Boston competes with Raleigh

entertainment

hotspot

hotspot

entertainment